<DOC>
	<DOCNO>NCT01527110</DOCNO>
	<brief_summary>This study open-label , multi-center , single arm study evaluate safety efficacy IV zanamivir 600mg twice daily 5 day hospitalize subject laboratory confirm influenza infection .</brief_summary>
	<brief_title>A Study Intravenous Zanamivir Treatment Hospitalized Patients With Influenza Infection</brief_title>
	<detailed_description>Adult subject adolescent subject ( â‰¥50 kg ) normal renal function receive 600mg per dose . Subjects renal impairment receive adjust dose base calculated creatinine clearance . The initial 5 day treatment course may extend 5 additional day viral shed determined ongoing clinical symptom warrant treatment IV zanamivir . The study duration approximately 28 day subject whose treatment duration 5 day , approximately 33 day subject whose treatment duration extend maximum 10 day . The study consist Pre-dose Baseline Assessments ( Day 1 ) , During Treatment Assessments ( Days 1 5 , Day 10 ) , Follow-up Assessments follow day : Post-Treatment +2 , +5 , +9 , +16 +23 Days . For subject discharge hospital , Post-Treatment +2 , +5 , +9 +16 Days Assessments make telephone contact .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Male female age great equal 16 year age ; female eligible enter participate study : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) ; , 2. childbearing potential , negative pregnancy test Baseline , agree use protocol specify method birth control study . Subjects laboratory confirm influenza determine positive result rapid antigen test ( RAT ) influenza A influenza B , laboratory test influenza include limited influenza virus antigen test , virus culture RTPCR test . Presence fever [ oral temperature &gt; =38 deg C , rectal , tympanic &gt; =38.5 deg C axilla &gt; =37.4 deg C ] Baseline . However , requirement waive subject history fever within 48 hour prior Baseline administer antipyretic ( ) 48 hour prior Baseline . Hospitalized subject symptomatic influenza define ANY follow . 1 . Moderate severe tachypnea ( respiratory rate &gt; =24/minute ) OR 2 . Moderate severe dyspnea ( unable speak full sentence ) OR 3 . Arterial oxygen saturation &lt; 95 % room air transcutaneous method , need supplemental oxygenation ventilatory support [ mechanical ventilation , bilevel positive airway pressure ( bipap ) , continuous positive airway pressure ( cpap ) ] , increase oxygen supplementation requirement &gt; =2 litres subject chronic oxygen dependency . For subject history chronic hypoxia ( without supplemental oxygen ) , arterial oxygen saturation least 3 % patient 's historical baseline oxygen saturation satisfy criterion OR 4 . Hemodynamic instability , define systolic blood pressure &lt; 90 mmHg heart rate &gt; 100 beat per minute OR 5 . Subject become dehydrated need wholebody management hospitalization . Onset influenza symptom within 6 day prior study enrolment . Symptoms may include cough , dyspnea , sore throat , feverishness , myalgia , headache , nasal symptom ( rhinorrhea , congestion ) , fatigue , diarrhea , anorexia , nausea vomiting . Subjects/legally acceptable representative unconscious adult willing able give write informed consent participate study , subject willing adhere procedure state protocol . Subjects , opinion investigator , likely survive beyond 48 hour Baseline . Subjects consider require concurrent therapy another influenza antiviral medication . Subjects know suspected hypersensitive component study medication . Subjects require Extra Corporeal Membrane Oxygenation ( ECMO ) Baseline ( enrol subject subsequently require ECMO may continue study ) . Liver toxicity criterion base local laboratory result obtain Baseline : 1 . ALT AST &gt; =3xULN bilirubin &gt; =2xULN 2 . ALT &gt; =5xULN Underlying chronic liver disease evidence severe liver impairment ( ChildPugh Class C ) . History severe cardiac disease clinically significant arrhythmia ( either ECG history ) , opinion investigator subinvestigator , interfere safety individual subject . Females pregnant ( positive urine serum pregnancy test Baseline ) breastfeeding . QT criterion Baseline define : 1 . QTcB QTcF &gt; 480 msec 2 . If subject bundle branch block criterion QTcB QTcF &gt; 510 msec Subject participate study use investigational drug previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>zanamivir</keyword>
	<keyword>Seasonal Influenza</keyword>
	<keyword>H1N1</keyword>
	<keyword>intravenous</keyword>
	<keyword>neuraminidase inhibitor</keyword>
	<keyword>Pandemic</keyword>
	<keyword>Relenza</keyword>
	<keyword>Influenza B virus</keyword>
	<keyword>Influenza A virus</keyword>
</DOC>